Skip to main content
Premium Trial:

Request an Annual Quote

People in the News: John Thompson, Christopher Cunniff


Transgenomics has appointed John Thompson as a Class II director of the firm. He will also serve on the audit committee of the company's board of directors. Thompson was previously senior vice president of strategy and corporate development at Invitrogen and was also previously senior vice president of strategy and business development at Dexter.

New York-Presbyterian/Weill Cornell Medical Center has appointed Christopher Cunniff to the director of the division of medical genetics. Previously, Cunniff was chief of medical and molecular genetics at the University of Arizona College of Medicine. He also served as co-medical director of the Children's Clinics for Rehabilitative Services and was recently a professor of pediatrics with joint appointments in pathology, public health, and obstetrics and gynecology at the University of Arizona College of Medicine. He also previously served as secretary of the American College of Medical Genetics and as president of the American Board of Medical Genetics.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.